Drug firm Zydus Cadila on Thursday said it has applied for emergency use authorisation (EUA) with the Indian drug regulator for its three-dose COVID-19 vaccine ZyCoV-D, and plans to manufacture......
'Someone may have diabetes, but at what level the disease qualifies as a comorbid condition is something a doctor will decide upon and certify accordingly.' IMAGE: COVID-19 vaccination in Jaipur,......
The Drugs Controller General of India has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults. A release by Cadila......
Amid surging COVID-19 cases in the country, the government on Tuesday waived customs duty on Remdesivir, its raw materials and other components used to make the antiviral drug. The move would help......
The government plans to double the production of antiviral drug remdesivir to around 3 lakh vials per day over the next 15 days, to make it available readily for the treatment of COVID-19.......
Cadila Healthcare Ltd has informed BSE that pursuant to Order dated January 31, 2003 passed by Hon'ble High Court of Gujarat in the matter of approval of Scheme of Amalgamation of German Remedies......
Cadila Healthcare Ltd board approved amalgamation of German Remedies Ltd, Recon Healthcare Ltd, Zydus Pathline Ltd & Zoom Properties Ltd with the company.The boards of Cadila Health Care and German......
Cadila Healthcare Ltd has posted a net profit of Rs 172.91 million for the quarter ended December 31, 2002 as compared to Rs 147.03 million for the quarter ended December 31, 2001. Total income has......
A meeting of the board of Cadila Healthcare Ltd will be held on January 29 to consider the quarterly results for the third quarter ended December 31, 2002.BSE Code:...
The Board of Directors of German Remedies Ltd at their meeting held on January 15, 2003 decided in principle under Section 391/394 and other applicable provisions of the Companies Act 1956 for the......